An international clinical trial has delivered a potentially practice-changing verdict for millions of women diagnosed with breast cancer: a gene expression test can reliably identify those who may safely forgo chemotherapy and its often-debilitating side effects. The OPTIMA study, presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, enrolled over 4,000 participants across the UK, Scandinavia, Australia, New Zealand, and Thailand. Researchers used the Prosigna assay to analyse the activity of 50 genes within tumour tissue and found that more than two-thirds of patients with hormone-sensitive breast cancer that had spread to nearby lymph nodes could be treated with hormone therapy alone, with no increased risk of recurrence. Viewed from London, where University College London led the trial, the results mark a decisive step toward precision oncology; clinicians in Milan and Madrid note the findings will reverberate through national health systems still grappling with overtreatment.

The Chicago conference also spotlighted a parallel ambition in cancer care: catching tumours before they cause symptoms. The NHS-Galleri trial, involving nearly 143,000 asymptomatic Britons, assessed whether an annual blood test that detects DNA shed by more than 50 cancer types could reduce late-stage diagnoses. While the study did not meet its primary endpoint of a statistically significant reduction in stage 4 cancers, it achieved a notable secondary result: for cancers not routinely screened, the test cut the most advanced diagnoses by over a fifth in the second and third years of screening. American commercial interests are watching closely; Silicon Valley firm Grail already offers the Galleri test for $950 in the United States, though analysts in Washington caution that cost-effectiveness and overdiagnosis concerns remain unresolved.

As survival rates inch upward, the quality of that extended life has drawn fresh scrutiny. A separate study published in the Journal of Clinical Oncology found that yoga significantly reduced insomnia, fatigue, and mood disturbances among cancer survivors — ailments that can persist for years after treatment. The trial, funded by the US National Cancer Institute, underscores a growing recognition in survivorship medicine that psychological and physical rehabilitation must sit alongside cutting-edge therapeutics.

Taken together, these advances sketch a future in which a blood draw might alert a healthy adult to an incipient malignancy, a rapid genetic test could then spare them the blunt instrument of chemotherapy, and a tailored regimen of yoga might restore their wellbeing after cure. Yet the gulf between innovation and access remains wide. In lower-income countries, where the Galleri test’s price tag represents months of an average wage and gene-expression profiling is scarcely available, the new tools risk widening global health divides. Diplomats and health ministers gathering for the World Health Assembly in Geneva next week are expected to debate whether multilateral procurement mechanisms could bring such diagnostics within reach — a conversation that will test the international community’s commitment to turning scientific breakthroughs into equitable outcomes.